A Phase I Trial of Pomalidomide for Children With Recurrent, Progressive or Refractory CNS Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Pomalidomide (Primary)
- Indications CNS cancer; Nervous system neoplasms
- Focus Adverse reactions; Pharmacokinetics
- 13 Apr 2018 Planned primary completion date changed from 31 Mar 2018 to 31 Mar 2020.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 15 Dec 2016 Status changed from recruiting to active, no longer recruiting.